Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1997-01-14
1998-09-22
LeGuyader, John L.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 231, 435 6, 435 911, 4351723, 435325, 435366, 514 44, C07H 2104, C12Q 168, A61K 4800
Patent
active
058115374
ABSTRACT:
The present invention is directed to oligonucleotides comprising nucleotide sequences sufficiently complementary to conserved regions of human immunodeficiency virus genetic material such that when bound to said region, the oligonucleotides effectively prevent expression of the genetic material.
REFERENCES:
patent: 4415732 (1983-11-01), Caruthers et al.
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4725677 (1988-02-01), Koster et al.
patent: 4959463 (1990-09-01), Froehler et al.
patent: 5110802 (1992-05-01), Cantin et al.
patent: 5166195 (1992-11-01), Ecker
Beal et al., "Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation" Science (1992) 251:1360-1363.
Bennett et al., "Cationic lipids enhance cellular uptake and activity of phosphorothioate entisense oligonucleotides" Mol. Pharmacol. (1992) 41:1023-1033.
Capobianco et al., "One pot solution synthesis of cyclic oligodeoxyribonucleotides" Nucl. Acids Res. (1990) 18:2661-2669.
Cooney et al., "Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro" Science (1988) 241:456-459.
Degols et al., "Antisense inhibitors of HIV: problems and perspectives" Antiviral Res. (1992) 17:279-287.
Drug & Market Develop. "Antisense/oligonucleotide therapeutics: Part 2--Company update" (1993) 4(7/8):179-195.
Fedorova et al., "Complementary addressed modification of double-stranded DNA within a ternary complex" FEBS Letters (1988) 228:273-276.
Froehler et al., "Oligodeoxynucleotides containing C-5 propyne analogs of 2'-deoxyuridine and 2'-deoxycytidine" Tetrahedron Letters (1992) 33:5307-5310.
Froehler et al., "Triple-helix formation and cooperative binding by oligodeoxynucleotides with a 3'-3' internucleotide junction" Biochem. (1992) 31:1603-1609.
Goodchild et al., "Inhibition of human immunodeficiency virus replication by antisense oligodeoxynucleotides" Proc. Natl. Acad. Sci. USA (1988) 85:5507-5511.
Horne et al., "Recognition of mixed-sequence duplex DNA by alternate-strand triple-helix formation" J. Am. Chem. Soc. (1990) 112:2435-2437.
Iverson et al., "Nonenzymatic sequence-specific cleavage of single-stranded DNA to nucleotide resolution. DNA methyl thioether probes" J. Am. Chem. Soc. (1987) 109:1241-1243.
Johnston et al., "Present status and future prospects for HIV therapies" Science (1993) 260:1286-1293.
Knorre et al., "Reactive oligonucleotide derivatives and sequence-specific modification of nucleic acids" Biochimie (1985) 67:785-789.
Kole et al., "Pre-mRNA splicing as a target for antisense oligonucleotides" Advanced Drug Delivery Reviews (1991) 6:271-286.
Lee et al., "Interaction of psoralen-derivatized oligodeoxyribonucleoside methylphosphonates with single-stranded DNA" Biochem. (1988) 27:3197-3203.
Lelen, "Ag-biotechnology companies move forward on heels of the FDA statement on biofoods" Genet. Eng. News (1992) 12(11):1, 21-22.
Loose-Mitchell, "Antisense nucleic acids as a potential class of pharmaceutical agents" TIPS (1988) 9:45-47.
Marcus-Sekura, "Techniques for using antisense oligodeoxyribonucleotides to study gene expression" Anal. Biochem. (1988) 172:289-295.
Mathews et al., Analytical strategies for the use of DNA probes Anal. Biochem. (1988) 169:1-25.
Matsukura et al., "A new concept in AIDS treatment: An antisense approach and its current status towards clinical application" Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS, Wickstrom, E., ed., (1991) Wiley-Liss, Inc., New York, pp. 159-178.
Matteucci et al., "Synthesis and crosslinking properties of a deoxyoligonucleotide containing N.sup.6,N.sup.6 --ethanodeoxyadenosine" Tetrahedron Letters (1987) 28:2469-2472.
McGraw et al., "Sequence-dependent oligonucleotide-target duplex stabilities: Rules from empirical studies with a set of twenty-mers" Biotechniques (1990) 8:674-678.
Meyer et al., "Efficient, specific cross-linking and cleavage of DNA by stable, synthetic complementary oligodeoxynucleotides" J. Am. Chem. Soc. (1989) 111:8517-8519.
Milligan et al., "Current concepts in antisense drug design" Med. Chem. (1993) 36:1922-1937.
Praseuth et al., "Sequence-specific binding and photocrosslinking of I and J oligodeoxynucleotides to the major groove of DNA via triple-helix formation" Proc. Natl. Acad. Sci. USA (1988) 85:1349-1353.
Ratajczak et al., "In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides" Proc. Natl. Acad. Sci. USA (1992) 89:11823-11827.
Ratner et al., "Complete nucleotide sequence of the AIDS virus, HTLV-III" Nature (1985) 313:277-284.
Rittner et al., "Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1" NAR (1991) 19:1421-1426.
Sanford, "Applying the PCT principle to AIDS", J. Theor. Biol. (1988) 130:469-480.
Seela et al., "Oligomers with alternating thymidine and 2'--deoxytubercidin: duplex stabilization by a 7-deazapurine base" Biochem. (1985) 24:7556-7561.
Seela et al., "Palindromic octa- and dodecanucleotides containing 2'--deoxytubercidin: synthesis, hairpin formation, and recognition by the endodeoxyribonuclease EcoRI" Biochem. (1987) 26:2232-2238.
Seela et al., "Palindromic oligonucleotides containing octamers and recognition by the endodeoxyribonuclease EcoRI" Nuc. Acids Res. (1986) 14:2319-2332.
Shaw et al., "Specific, high-efficiency, triple-helix-mediated cross-linking to duplex DNA" J. Am. Chem. Soc. (1991) 113:7765-7766.
Shibahara et al., "Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives" NAR (1989) 17:239-252.
Stein et al., "Oligonucleotides as inhibitors of gene expression: A review" Cancer Res. (1988) 48:2659-2668.
Stein et al., "Antisense oligonucleotides as therapeutic agents--is the bullet really magical?" Science (1993) 261:1004-1011.
Sterling, "Systemic antisense treatment reported" Genet. Eng. News (1992) 12(12):1, 28.
Thierry et al., "Liposomal delivery as a new approach to transport antisense oligonucleotides" Gene Regulation: Biology of Antisense RNA and DNA, Erickson et al., eds., (1992) Raven Press, New York, pp. 147-161.
Uhlmann et al., "Antisense oligonucleotides: A new therapeutic principle" Chem. Rev. (1990) 90:544-584.
van de Sande et al., "Parallel stranded DNA" Science (1988) 241:551-557.
Van der Krol et al., "Modulation of eukaryotic gene expression by complementary RNA or DNA sequences" BioTechniques (1988) 6:958-976.
Vlassov et al., "Sequence-specific chemical modification of double-stranded DNA with alkylating oligodeoxynucleotide derivatives" Gene (1988) 72:313-322.
Wagner, "Gene inhibition using antisense oligodeoxynucleotides" Nature (1994) 372:333-335.
Walder, "Antisense DNA and RNA: progress and prospects" Genes & Devel. (1988) 2:502-504.
Webb et al., "Hybridization triggered cross-linking of deoxyoligonucleotides" Nucl. Acids Res. (1986) 14(19):7661-7674.
Webb et al., "Sequence-specific cross-linking of deoxyoligonucleotides via hybridization-triggered alkylation" J. Am. Chem. Soc. (1986) 108:2764-2765.
Weiss, "Upping the antisense ante" Science News (1991) 139:108-109.
Whitesell et al., "Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: Implications for the therapeutic application within the central nervous system" Proc. Natl. Acad. Sci. USA (1993) 90:4665-4669.
Young et al., "Triple helix formation inhibits transcription elongation in vitro" Proc. Natl. Acad. Sci. USA (1991) 88:10023-10026.
Yu et al., Neurosci Res. (1991) 30:72-79. Provided as Biosis Acc No. 92138937.
Zon, "Oligonucleotide analogues as potential chemotherapeutic agents" Pharm. Res. (1988) 5:539-549.
Zon, "Synthesis of backbone-modified DNA analogues for biological applications" J. Pro. Chem. (1987) 6:131-145.
LeGuyader John L.
Lehnhardt Susan K.
Novopharm Biotech Inc.
LandOfFree
Antisense oligonucleotides targeted against human immunodeficien does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleotides targeted against human immunodeficien, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleotides targeted against human immunodeficien will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1622776